Lilly pushes retatrutide filing to early 2027 after two more Phase 3 wins
The company says it needs more time to compile manufacturing and quality-control data required by regulators before submitting the triple agonist.
MH
By Maren Holt · Senior Reporter, GLP-1
Jul 23 03:00 ETSource: CNBC
The wire
- 01In adults with obesity and type 2 diabetes, retatrutide cut weight by up to 20.8% on average at 80 weeks; in severe obesity with cardiovascular disease, up to 22.6%, or 55.8 pounds.
- 02Lilly says it now has data to file globally for obesity, knee osteoarthritis pain and obstructive sleep apnea, positioning the GLP-1/GIP/glucagon agonist behind Zepbound and the pill Foundayo.
- 03Filing is now slated for the first quarter of 2027; adverse events were diarrhea, nausea and constipation, and the full trial data have not yet been peer-reviewed or published.
From the source
Read at cnbc.comEli Lilly says it will file for approval of next-generation obesity drug in 2027 as it clears two more trials
Eli Lilly on Thursday said it will file for approval of its next-generation obesity drug in the first quarter of 2027, as the treatment succeeds in two more late-stage trials.